Immunomedics INC (IMMU) Stock Price Declined While Ghost Tree Capital LLC Has Decreased Its Holding

Immunomedics, Inc. (NASDAQ:IMMU) LogoInvestors sentiment increased to 1.86 in 2018 Q2. Its up 0.60, from 1.26 in 2018Q1. It is positive, as 20 investors sold IMMU shares while 38 reduced holdings. 43 funds opened positions while 65 raised stakes. 139.30 million shares or 18.50% more from 117.56 million shares in 2018Q1 were reported. Ghost Tree Capital Limited Com holds 8.71% or 1.25M shares. California State Teachers Retirement System invested 0.01% of its portfolio in Immunomedics, Inc. (NASDAQ:IMMU). Alliancebernstein LP invested 0.01% of its portfolio in Immunomedics, Inc. (NASDAQ:IMMU). Tocqueville Asset Mngmt Limited Partnership has 0.01% invested in Immunomedics, Inc. (NASDAQ:IMMU) for 43,725 shares. Omega Advsrs has invested 0.33% in Immunomedics, Inc. (NASDAQ:IMMU). Alkeon Capital Mgmt Ltd reported 1.85 million shares. Axiom Invsts Ltd Co De holds 133,850 shares. Voloridge Invest Mgmt Lc, Florida-based fund reported 130,495 shares. Principal Fin Group Incorporated invested 0% of its portfolio in Immunomedics, Inc. (NASDAQ:IMMU). Suntrust Banks owns 15,200 shares or 0% of their US portfolio. Cap World Investors owns 785,000 shares. Credit Suisse Ag invested 0% of its portfolio in Immunomedics, Inc. (NASDAQ:IMMU). Geode Mngmt Llc reported 0.01% in Immunomedics, Inc. (NASDAQ:IMMU). Advisory Ser Limited Com holds 3,072 shares. Moreover, Fmr Ltd has 0.02% invested in Immunomedics, Inc. (NASDAQ:IMMU) for 8.49 million shares.

Since June 15, 2018, it had 2 insider purchases, and 0 selling transactions for $18.48 million activity.

Ghost Tree Capital Llc decreased its stake in Immunomedics Inc (IMMU) by 32.43% based on its latest 2018Q2 regulatory filing with the SEC. Ghost Tree Capital Llc sold 600,000 shares as the company’s stock declined 0.90% while stock markets rallied. The hedge fund held 1.25M shares of the health care company at the end of 2018Q2, valued at $29.59M, down from 1.85 million at the end of the previous reported quarter. Ghost Tree Capital Llc who had been investing in Immunomedics Inc for a number of months, seems to be less bullish one the $3.34 billion market cap company. The stock decreased 7.43% or $1.41 during the last trading session, reaching $17.57. About 2.31 million shares traded or 19.64% up from the average. Immunomedics, Inc. (NASDAQ:IMMU) has risen 107.13% since December 8, 2017 and is uptrending. It has outperformed by 91.51% the S&P500.

Ghost Tree Capital Llc, which manages about $339.79 million US Long portfolio, upped its stake in Assembly Biosciences Inc (NASDAQ:ASMB) by 85,000 shares to 235,000 shares, valued at $9.21 million in 2018Q2, according to the filing.

Analysts await Immunomedics, Inc. (NASDAQ:IMMU) to report earnings on February, 14. They expect $-0.31 earnings per share, down 63.16 % or $0.12 from last year’s $-0.19 per share. After $-0.35 actual earnings per share reported by Immunomedics, Inc. for the previous quarter, Wall Street now forecasts -11.43 % EPS growth.

More notable recent Immunomedics, Inc. (NASDAQ:IMMU) news were published by: Seekingalpha.com which released: “Immunomedics: Highly Investible Ahead Of PDUFA – Seeking Alpha” on November 27, 2018, also Nasdaq.com with their article: “IMMU Crosses Below Key Moving Average Level – Nasdaq” published on November 12, 2018, Seekingalpha.com published: “Hold On To Harsco – Cramer’s Lightning Round (12/3/18) – Seeking Alpha” on December 04, 2018. More interesting news about Immunomedics, Inc. (NASDAQ:IMMU) were released by: Zacks.com and their article: “Why Immunomedics (IMMU) Could Be Positioned for a Slump – Zacks.com” published on November 30, 2018 as well as Nasdaq.com‘s news article titled: “New Research Coverage Highlights Immunomedics, Surmodics, PDF Solutions, Stepan, Express Scripts Holding, and BioCryst Pharmaceuticals — Consolidated Revenues, Company Growth, and Expectations for 2018 – Nasdaq” with publication date: November 27, 2018.

Immunomedics, Inc. (NASDAQ:IMMU) Ratings Coverage

Among 5 analysts covering Immunomedics (NASDAQ:IMMU), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Immunomedics had 5 analyst reports since August 24, 2018 according to SRatingsIntel. The company was reinitiated on Thursday, November 8 by Jefferies. The company was maintained on Friday, August 24 by FBR Capital.

Immunomedics, Inc. (NASDAQ:IMMU) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.